Artelo Biosciences (ARTL) investor relations material

Company overview and business model

• Clinical-stage biopharmaceutical company focused on therapeutics targeting lipid-signaling modulation pathways, including the endocannabinoid system.

• Pipeline includes ART27.13 (dual cannabinoid agonist for cancer-related anorexia), ART26.12 (FABP5 inhibitor for chemotherapy-induced peripheral neuropathy and other indications), and ART12.11 (proprietary CBD cocrystal for multiple potential indications).

• Product candidates are developed under traditional regulated drug development standards, aiming for prescription-based commercialization post regulatory approval.

• Holds patents and licenses for key product candidates, with global intellectual property coverage.

Financial performance and metrics

• Gross proceeds from the March 2026 private placement offering were $10,996,902.70, with net proceeds of $10,031,902.37 after fees and expenses.

• If all warrants are exercised for cash, potential aggregate gross proceeds could reach approximately $31.4 million.

• Funds are allocated for working capital, general corporate purposes, and repayment of certain bridge debt.

Use of proceeds and capital allocation

• Proceeds from warrant exercises will be used for working capital, general corporate purposes, and repayment of bridge debt.

• Management retains broad discretion over the allocation of net proceeds.